The number of reported cases of venous thromboembolism associated with the Oxford- AstraZeneca vaccine in Denmark is lower than the expected number of cases in the population


An electronic population study of Denmark's hospital patient registry (Danish National Patient Registry, or DNPR) of
4.9 million adults estimated the number of thromboembolic events and the incidence of such events in the Danish
population between 2010 and November 2018.

Considering the calculated incidence, the number of expected events per month for a population of the same size as the vaccinated population was estimated. For people between the ages of 18 and 99, an estimated 736 events per month would be expected, while for people between ages 18 and 64, the expected number of events was estimated at 398 per month. The number of reported cases of venous
thromboembolism in the vaccinated population appears to be lower than the number of cases that would be expected in the general population.

However, such estimates have their limitations, and the risk of thromboembolic
events associated with this vaccine should continue to be monitored.

Source: Ostergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-
AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. March 2021. doi: 10.1016/S0140-

  • Share: